prednisolone succinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 2246 2920-86-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prednisolone succinate
  • prednisolone bisuccinate
  • prednisolone hemisuccinate
  • prednisolone sodium succinate
  • Molecular weight: 460.52
  • Formula: C25H32O8
  • CLOGP: 1.73
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 138.20
  • ALOGS: -3.98
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.22 mg/mL Bocci G, Oprea TI, Benet LZ
CL (Clearance) 1.46 mL/min/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 82 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 18
kinase-selectivity-class AXL,GRK2,MAP2K6 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.853 Moderate 0.70
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.70
rat-kpuu-brain Rat brain Kpuu 0.011 % Moderate 0.70

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 183.95 47.31 49 1162 32479 90594757
Stevens-Johnson syndrome 79.50 47.31 25 1186 29351 90597885
Lip erosion 73.75 47.31 13 1198 1225 90626011
Cholecystitis 56.67 47.31 17 1194 17023 90610213
Conjunctivitis 53.06 47.31 18 1193 26688 90600548
Circulatory collapse 50.32 47.31 17 1194 24887 90602349
Dermatitis exfoliative 49.20 47.31 12 1199 5524 90621712

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 169.07 30.57 61 2771 56666 110529801
Stevens-Johnson syndrome 74.41 30.57 32 2800 46869 110539598
Lip erosion 65.60 30.57 14 2818 1852 110584615
Polyneuropathy 61.36 30.57 25 2807 31987 110554480
Cholecystitis 42.15 30.57 18 2814 25864 110560603
Pneumonia 40.88 30.57 77 2755 876637 109709830
Conjunctivitis 40.62 30.57 19 2813 33773 110552694
Hyperthyroidism 40.02 30.57 18 2814 29243 110557224
Pneumothorax 39.83 30.57 19 2813 35266 110551201
Blister 33.75 30.57 35 2797 227341 110359126
Multiple organ dysfunction syndrome 33.29 30.57 29 2803 151681 110434786
Dermatitis exfoliative 32.96 30.57 12 2820 11335 110575132
Lymphocytosis 32.95 30.57 10 2822 5401 110581066
Respiratory disorder 32.16 30.57 21 2811 71361 110515106
Circulatory collapse 30.68 30.57 17 2815 42976 110543491

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35816 leprostatic drug
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:37962 adrenergic agent
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49103 drug metabolite
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50671 antithyroid drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:53784 antispasmodic drug
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:76595 nephroprotective agent
CHEBI has role CHEBI:77715 nasal decongestant
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:233423 antifibrotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Inflammation Indication
Cats Allergy and less severe stress conditions Indication
Dogs Inflammation Indication
Dogs Allergy and less severe stress conditions Indication
Dogs Shock Indication
Horses Inflammation Indication
Horses Allergy Indication

🐶 Veterinary products

ProductApplicantIngredients
Solu-Delta Cortef Sterile Powder Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.23 acidic
pKa2 12.65 acidic
pKa3 13.36 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D02156 KEGG_DRUG
4017988 VANDF
C0071840 UMLSCUI
TUA PDB_CHEM_ID
CHEMBL485659 ChEMBL_ID
DB14633 DRUGBANK_ID
C021322 MESH_SUPPLEMENTAL_RECORD_UI
656804 PUBCHEM_CID
55063 RXNORM
5347 MMSL
59710 MMSL
d00084 MMSL
002155 NDDF
002158 NDDF
006890 NDDF
1013811000202101 SNOMEDCT_US
116601002 SNOMEDCT_US
52388000 SNOMEDCT_US
C0032950 UMLSCUI
CHEBI:135745 CHEBI
CHEMBL1412530 ChEMBL_ID
DB00860 DRUGBANK_ID
1715-33-9 SECONDARY_CAS_RN
5755 PUBCHEM_CID
535 INN_ID
D011239 MESH_DESCRIPTOR_UI
G7080T74ON UNII
CHEBI:8378 CHEBI
G7080T74ON INXIGHT DRUGS

Pharmaceutical products:

None